Slide 1Out of Cycle HL7 RCRIM Meeting 25 April 2006 Berlin, Germany Slide 2 Initial Associate Charter Agreement 2001 Formed Clinical Trial Special Interest Group Elevated…

1. 1 CVs of selectedScientific Collaborators D A N I C A G R U J I C P H . D . | CELL (617) 599-3301 | HOM E (617) 427-7085 210 PARKER HILL AVENUE | BOSTON, MA 02120 [email protected]…

1. Paul K. Wotton, Ph.D. President and Chief Executive Officer July 2011 AMEX: AIS 2. 2 This presentation may contain forward-looking statements which are made pursuant to…

1. Paul K. Wotton, Ph.D. President and Chief Executive Officer September 2011 AMEX: AIS 2. 2 This presentation may contain forward-looking statements which are made pursuant…

Slide 1 THE CHANGING SHAPE OF PHARMACEUTICAL RISK PETER FELDSCHREIBER FOUR NEW SQUARE LINCOLN’S INN Slide 2 2 A Brief History 120 B.C: Mithradatum/Galene – global panacea,…

Slide 1 Retinal Degeneration: Progress in Basic Science and Movement to Clinical Trials Our Goal: To rapidly move from research at the laboratory bench to the clinic such…

Chikungunya Fever and the Development of Novel Vaccine Candidates Paige Adams, D.V.M., Ph.D. Sealy Center for Vaccine Development University of Texas Medical Branch Galveston,…

1. NANOTECHNOLOGY FORARTIFICIALREDBLOODCELL(OR) SYNTHETIC RBC 1 2.  Nanotechnology is defined as the fabrication of devices withprecision to the scale of 1 to 100 nanometers…

Out of Cycle HL7 RCRIM Meeting 25 April 2006 Berlin, Germany Initial Associate Charter Agreement 2001 Formed Clinical Trial Special Interest Group Elevated to Regulated Clinical…